ALZCUR.ST

AlzeCure Pharma AB (publ) [ALZCUR.ST] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ALZCUR.ST Stock Summary

In the News

ALZCUR.ST Financial details

Company Rating
-
Market Cap
127.28M
Income
-36.95M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
11
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-5.06
Forward P/E
-
PEG
1.02
P/S
-
P/B
5.74
P/C
-
P/FCF
-4.84
Quick Ratio
5.46
Current Ratio
5.81
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.59
EPS next Y
-
EPS next Q
-
EPS this Y
-48.72%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
33.33%
-
-
-
-
SMA20
-
SMA50
108.85%
SMA100
116.51%
Inst Own
-
Inst Trans
-
ROA
-94%
ROE
-82%
ROC
-1.17%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.595-6.54
52W High
-60.5%
52W Low
+137%
RSI
49.88
Rel Volume
0.13
Avg Volume
69.62K
Volume
9.29K
Perf Week
-4.05%
Perf Month
-20.47%
Perf Quarter
37.79%
Perf Half Y
31.67%
-
-
-
-
Beta
0.385
-
-
Volatility
0.04%, 0.17%
Prev Close
-0.42%
Price
2.37
Change
-1.25%

Something similar

Top by Market Cap
3V64.DE
MSF.DE
TL0.DE
EMBASSY.NS
CMC.DE
Same Sector
096760.KS
BNR
AVCT.L
HYBT
ARAY
Same Price Range
AIGE.L
3998.HK
LGHL
1730.HK
CELL.MI
Similar Market Cap
ADAG
FVAM
LTRPA
AZBO
KAN.ST

Company Profile

Healthcare Drug Manufacturers - Specialty & Generic
  • Volume Average 69.62K
  • Market Capitalization 127.28M
  • Employee 11
  • CEO Mr. Martin Jönsson
  • Headquarters Huddinge,SE
  • IPO Date 2018-11-28
  • Website https://www.alzecurepharma.se

AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is developing drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its pipeline drug candidates include ACD856, which is in phase I clinical trial for Alzheimer's disease, sleep disorders, traumatic brain injuries, and Parkinson's disease; ACD857, ACD679, and ACD680 for Alzheimer's disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.